IBRX
HealthcareImmunityBio, Inc. · Biotechnology · $8B
IBRX Price History
-53.8% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in ImmunityBio, Inc.?
Based on ImmunityBio, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Unlock Full IBRX Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓Detailed 6-pillar UQS breakdown with exact scores
- ✓All 29 metrics with sector-calibrated comparisons
- ✓6 investor presets (Buffett, Munger, Lynch, Wood, Graham, Balanced)
- ✓Watchlist tracking with score alerts
- ✓AI-generated investment perspectives across 6 preset views
- ✓Score history chart with change notifications
Pro Analysis
IBRX — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 9, 2026 | 41.3 | 25.8 | 19.0 | 100.0 | 67.4 | 0.0 | -2.3 |
| Apr 2, 2026 | 43.6 | 25.8 | 19.0 | 100.0 | 82.4 | 0.0 | — |
IBRX — Pillar Breakdown
Quality
— 25.8/100 (25%)ImmunityBio, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 100.0/100 (20%)ImmunityBio, Inc. is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 82.4/100 (15%)ImmunityBio, Inc. carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)ImmunityBio, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 19/100 (25%)ImmunityBio, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for IBRX.
Score Composition
Financial Data
More Stock Analysis
How is the IBRX UQS Score Calculated?
The UQS (Unified Quality Score) for ImmunityBio, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses ImmunityBio, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether ImmunityBio, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.